Prot #D4190C00011: A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

Effective start/end date7/24/157/24/18


  • PRA Health Sciences (Prot #D4190C00011 // Prot #D4190C00011)
  • MedImmune, LLC (Prot #D4190C00011 // Prot #D4190C00011)